The measurement of autotaxin (ATX) has been covered by the national health insurance in Japan since June 2018 as an auxiliary method of quantifying the degree of liver fibrosis in patients with chronic liver disease and cirrhosis [75]. The gene discussed is ENPP2; the disease is Cirrhosis.